Objective: To investigate the effectiveness of stilamin in malignant bowel obstruction (MBO) due to advanced gastrointestinal carcinoma patients. Methods: 62 patients with MBO due to gastrointestinal carcinoma were randomly divided into two groups: routine therapy group (control group 30 patients) and stilamin group (32 patients). Stilamin group received routine therapy combined with stilamin (6 mg/d) by 24 hours continuous infusion for three to twelve days. The curative effec-tiveness was observed and compared between the two groups. Results: After treatment, the clinical symptoms of abdominal distention and abdominal pain were relieved significantly in stilamin group compared with the control group (84.4% vs 57.6%; P < 0.05). The exhaust of anus was more earlier (62.1% vs 25.6%; P < 0.05), and the average volume of gastrointestinal de-compression reduced more rapidly in stilamin group compared with the control group [(216 ± 158) mL/d vs (522 ± 184) mL/d; P < 0.001), smaller and less fluid-air in the intestinal and in the colon at the 81.3% of patients plain abdominal radiography were observed in stilamin group. Quality of life, evaluated with Karnofsky score (57 ± 7 vs 45 ± 9; P < 0.01), was improved significantly. Conclusion: The administration of stilamin, in combination with routine treatment can be very effective in the management of MBO. It can effectively relieve the symptoms of MBO and improve the quality of life in patients. Methods: 62 patients with MBO due to gastrointestinal carcinoma were randomly divided into two groups: routine therapy group (control group 30 patients) and stilamin group (32 patients). Stilamin group received routine therapy combined with stilamin (6 mg / d) by 24 hours continuous infusion for three to twelve days. The curative effec-tiveness was observed and compared between the two groups. the clinical symptoms of abdominal distention and abdominal pain were relieved significantly in stilamin group compared with the control group (84.4% vs 57.6%; P <0.05). The exhaust of anus was more earlier (62.1% vs 25.6%; P <0.05) , and the average volume of gastrointestinal de-compression reduced more rapidly in stilamin group compared with the control group [(216 ± 158) mL / d vs (522 ± 184) mL / d; P <0.001), smaller and les s fluid-air in the intestinal and in the colon at the 81.3% of patients plain abdominal radiography were observed in stilamin group. Quality of life, evaluated with Karnofsky score (57 ± 7 vs 45 ± 9; P <0.01), was improved significantly. Conclusion: The administration of stilamin, in combination with routine treatment can be very effective in the management of MBO. It can effectively relieve the symptoms of MBO and improve the quality of life in patients.